Skip to main content
Valiant Laboratories Limited logo

Valiant Laboratories Limited — Investor Relations & Filings

Ticker · VALIANTLAB ISIN · INE0JWS01017 LEI · 335800VKNJKWJ4LD6855 BSE.NS Manufacturing
Open in API
Filings indexed 168 across all filing types
Latest filing 2026-05-20 Major Shareholding Noti…
Country IN India
Listing BSE.NS VALIANTLAB

About Valiant Laboratories Limited

https://www.valiantlabs.in/

Valiant Laboratories Limited specializes in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs, with a primary focus on the production of Paracetamol. The company operates dedicated manufacturing facilities designed for the large-scale synthesis of analgesic and antipyretic compounds. By maintaining rigorous quality control standards and process efficiencies, it serves as a key supplier for formulations across various therapeutic segments. Its core business activities encompass the chemical processing and distribution of high-grade medicinal ingredients, catering to a diverse range of healthcare manufacturers. The organization prioritizes technical excellence in API synthesis and the optimization of production workflows to ensure a consistent supply of essential pharmaceutical components.

Recent filings

Filing Released Lang Actions
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 93% confidence The document is an official intimation under SEBI Takeover Regulations disclosing a substantial acquisition of shares (34.26% stake) by Valiant Organics Ltd. from Dhanvallabh Ventures LLP, complying with Regulation 10(5) of the Substantial Acquisition of Shares and Takeovers Regulations. This is a statutory notification of change in significant shareholding levels, matching the definition of Major Shareholding Notification.
2026-05-20 English
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Major Shareholding Notification Classification · 86% confidence The document is a formal stock exchange filing under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations for the off-market purchase of shares, showing pre- and post-transaction shareholding percentages and regulatory citations. This is not an earnings release or financial report but a disclosure of a material change in share ownership crossing thresholds. It therefore falls under Major Shareholding Notification (MRQ).
2026-05-20 English
Updates
Major Shareholding Notification Classification · 98% confidence The document is an official intimation to stock exchanges under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations 2011, disclosing a proposed inter-se transfer of promoter shareholding that alters major share percentages. It is not announcing a full takeover bid or open offer, but rather a change in significant share ownership crossing regulatory thresholds. This matches our definition for Major Shareholding Notification (Code: MRQ).
2026-05-19 English
Please find enclosed
Major Shareholding Notification Classification · 85% confidence The document is a formal intimation to stock exchanges under SEBI’s Substantial Acquisition of Shares and Takeovers Regulations, 2011 (Regulation 10(5)), disclosing the proposed acquisition/transfer of 34.26% of equity shares between promoter entities. It is not an earnings release, annual report, or proxy solicitation; rather it is a threshold-crossing shareholding notification. This matches the "Major Shareholding Notification" category (Code: MRQ).
2026-05-19 English
Valiant Laboratories Limited announces evaluation of Restructuring options.
Regulatory Filings Classification · 80% confidence The document is a press release sent to the stock exchanges under SEBI LODR Regulation 30, notifying a Board decision to explore corporate restructuring options. It does not contain actual financial statements, governance rules, or a finalized M&A transaction; rather it is a routine regulatory disclosure. Therefore it falls under the generic “Regulatory Filings” category.
2026-05-16 English
Press Release
Regulatory Filings Classification · 90% confidence The document is a press release submitted under SEBI Listing Regulation 30 notifying the stock exchanges of the Board’s decision to explore potential restructuring options. It contains no financial statements or detailed performance data, nor is it an annual or interim report. It is a general regulatory disclosure rather than the report itself or a management change notice, a dividend, or an M&A completion. Thus it falls under the catch-all category for miscellaneous regulatory announcements: Regulatory Filings (RNS).
2026-05-16 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.